Loading...
Edwards Lifesciences Community
NYSE:EW Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 59 Fair Values set on narratives written by author
Community Investing Ideas
Early TAVR And EVOQUE Launches Will Expand Access
Key Takeaways Strategic product launches, like the TAVR approval and EVOQUE, position Edwards for significant revenue growth and expanded market share. Investments in surgical innovation and operational efficiency mitigate financial threats, enhance global therapy adoption, and stabilize earnings.
0users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
AN
US$87.73
14.3% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
10.02% p.a.
Profit Margin
23.72%
Future PE
35.06x
Share price in 2028
US$108.74